APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Outlook and Growth Opportunities 2026

6 March 2026195 pages

Choose your research edition.

Industry ResearchCardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution market include Deepwise, Lepu Medical, NeuMiva, G K Healthcare, Sense Time, United Imaging, Infervision, Shukun and FOSUN AITROX, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution market.

Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Segment by Company

Deepwise

Lepu Medical

NeuMiva

G K Healthcare

Sense Time

United Imaging

Infervision

Shukun

FOSUN AITROX

Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Segment by Type

Public Cloud

Private Cloud

Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Segment by Application

Hospital

Clinic

Imaging Center

Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution key companies, revenue, market share, and recent developments.

3. To split the Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution significant trends, drivers, influence factors in global and regions.

6. To analyze Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution industry.

Chapter 3: Detailed analysis of Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Trends Table 2. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Drivers Table 3. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Opportunities and Challenges Table 4. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Restraints Table 5. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue Share by Company (2021-2026) Table 7. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Key Company Manufacturing Base & Headquarters Table 9. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company, Product Type & Application Table 10. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Public Cloud Table 15. Significant Companies of Private Cloud Table 16. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type (2021-2026) Table 20. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Imaging Center Table 24. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application (2021-2026) Table 28. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application (2027-2032) Table 29. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Region (2021-2026) Table 32. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Region (2027-2032) Table 34. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Market Share by Country (2021-2026) Table 37. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Market Share by Country (2027-2032) Table 39. Deepwise Company Information Table 40. Deepwise Business Overview Table 41. Deepwise Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Deepwise Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 43. Deepwise Recent Development Table 44. Lepu Medical Company Information Table 45. Lepu Medical Business Overview Table 46. Lepu Medical Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Lepu Medical Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 48. Lepu Medical Recent Development Table 49. NeuMiva Company Information Table 50. NeuMiva Business Overview Table 51. NeuMiva Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. NeuMiva Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 53. NeuMiva Recent Development Table 54. G K Healthcare Company Information Table 55. G K Healthcare Business Overview Table 56. G K Healthcare Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. G K Healthcare Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 58. G K Healthcare Recent Development Table 59. Sense Time Company Information Table 60. Sense Time Business Overview Table 61. Sense Time Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sense Time Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 63. Sense Time Recent Development Table 64. United Imaging Company Information Table 65. United Imaging Business Overview Table 66. United Imaging Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. United Imaging Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 68. United Imaging Recent Development Table 69. Infervision Company Information Table 70. Infervision Business Overview Table 71. Infervision Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Infervision Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 73. Infervision Recent Development Table 74. Shukun Company Information Table 75. Shukun Business Overview Table 76. Shukun Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Shukun Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 78. Shukun Recent Development Table 79. FOSUN AITROX Company Information Table 80. FOSUN AITROX Business Overview Table 81. FOSUN AITROX Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. FOSUN AITROX Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio Table 83. FOSUN AITROX Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Image Figure 2. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Size (2021-2032) & (US$ Million) Figure 4. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Public Cloud Image Figure 8. Private Cloud Image Figure 9. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Imaging Center Image Figure 15. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application (2021-2032) Figure 18. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032) & (US$ Million) Figure 21. North America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032) & (US$ Million) Figure 27. South America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Public Cloud
  • Private Cloud
Applications
  • Hospital
  • Clinic
  • Imaging Center
Companies covered
  • Deepwise
  • Lepu Medical
  • NeuMiva
  • G K Healthcare
  • Sense Time
  • United Imaging
  • Infervision
  • Shukun
  • FOSUN AITROX

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Dynamics
  1. 2.1 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Trends
  2. 2.2 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Drivers
  3. 2.3 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Opportunities and Challenges
  4. 2.4 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Industry Restraints
3 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market by Company
  1. 3.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Revenue Ranking in 2025
  2. 3.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue by Company (2021-2026)
  3. 3.3 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Ranking (2024-2026)
  4. 3.4 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Manufacturing Base and Headquarters
  5. 3.5 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Product Type and Application
  6. 3.6 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market by Type
  1. 4.1 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Type Introduction
  2. 4.1.1 Public Cloud
  3. 4.1.2 Private Cloud
  4. 4.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Type
  5. 4.2.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Type (2021-2032)
  7. 4.2.3 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type (2021-2032)
5 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Market by Application
  1. 5.1 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Imaging Center
  5. 5.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Application
  6. 5.2.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Application (2021-2032)
  8. 5.2.3 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application (2021-2032)
6 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Regional Value Analysis
  1. 6.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032)
  7. 6.3.2 North America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032)
  10. 6.4.2 Europe Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032)
  16. 6.6.2 South America Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Country, 2025 VS 2032
7 Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Country-level Value Analysis
  1. 7.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Deepwise
  2. 8.1.1 Deepwise Company Information
  3. 8.1.2 Deepwise Business Overview
  4. 8.1.3 Deepwise Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Deepwise Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  6. 8.1.5 Deepwise Recent Developments
  7. 8.2 Lepu Medical
  8. 8.2.1 Lepu Medical Company Information
  9. 8.2.2 Lepu Medical Business Overview
  10. 8.2.3 Lepu Medical Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Lepu Medical Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  12. 8.2.5 Lepu Medical Recent Developments
  13. 8.3 NeuMiva
  14. 8.3.1 NeuMiva Company Information
  15. 8.3.2 NeuMiva Business Overview
  16. 8.3.3 NeuMiva Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  17. 8.3.4 NeuMiva Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  18. 8.3.5 NeuMiva Recent Developments
  19. 8.4 G K Healthcare
  20. 8.4.1 G K Healthcare Company Information
  21. 8.4.2 G K Healthcare Business Overview
  22. 8.4.3 G K Healthcare Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  23. 8.4.4 G K Healthcare Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  24. 8.4.5 G K Healthcare Recent Developments
  25. 8.5 Sense Time
  26. 8.5.1 Sense Time Company Information
  27. 8.5.2 Sense Time Business Overview
  28. 8.5.3 Sense Time Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sense Time Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  30. 8.5.5 Sense Time Recent Developments
  31. 8.6 United Imaging
  32. 8.6.1 United Imaging Company Information
  33. 8.6.2 United Imaging Business Overview
  34. 8.6.3 United Imaging Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  35. 8.6.4 United Imaging Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  36. 8.6.5 United Imaging Recent Developments
  37. 8.7 Infervision
  38. 8.7.1 Infervision Company Information
  39. 8.7.2 Infervision Business Overview
  40. 8.7.3 Infervision Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Infervision Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  42. 8.7.5 Infervision Recent Developments
  43. 8.8 Shukun
  44. 8.8.1 Shukun Company Information
  45. 8.8.2 Shukun Business Overview
  46. 8.8.3 Shukun Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shukun Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  48. 8.8.5 Shukun Recent Developments
  49. 8.9 FOSUN AITROX
  50. 8.9.1 FOSUN AITROX Company Information
  51. 8.9.2 FOSUN AITROX Business Overview
  52. 8.9.3 FOSUN AITROX Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Revenue and Gross Margin (2021-2026)
  53. 8.9.4 FOSUN AITROX Cardiovascular and Cerebrovascular AI-assisted Diagnosis Solution Product Portfolio
  54. 8.9.5 FOSUN AITROX Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst